Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) CFO Paul J. Clancy sold 6,079 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $707,048.49. Following the transaction, the chief financial officer now directly owns 95,093 shares of the company’s stock, valued at $11,060,266.83. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $108.60 on Friday. The company has a market capitalization of $24,045.78, a price-to-earnings ratio of 21.39, a price-to-earnings-growth ratio of 0.91 and a beta of 1.16. The company has a current ratio of 3.10, a quick ratio of 2.51 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. Alexion Pharmaceuticals’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 EPS. equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.25 earnings per share for the current year.

A number of equities analysts have recently issued reports on the company. Piper Jaffray Companies reissued an “overweight” rating and set a $170.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Royal Bank of Canada increased their target price on Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Stifel Nicolaus lowered their price target on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a report on Tuesday, October 24th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a report on Tuesday, October 31st. Finally, Raymond James Financial restated an “outperform” rating and issued a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $153.14.

A number of large investors have recently made changes to their positions in ALXN. Dimensional Fund Advisors LP grew its holdings in Alexion Pharmaceuticals by 13.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 364,268 shares of the biopharmaceutical company’s stock valued at $44,323,000 after buying an additional 42,809 shares during the last quarter. AHL Partners LLP acquired a new stake in Alexion Pharmaceuticals during the 2nd quarter valued at $2,187,000. Macquarie Group Ltd. grew its holdings in Alexion Pharmaceuticals by 76.1% during the 2nd quarter. Macquarie Group Ltd. now owns 131,994 shares of the biopharmaceutical company’s stock valued at $16,060,000 after buying an additional 57,026 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in Alexion Pharmaceuticals by 30.2% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 50,577 shares of the biopharmaceutical company’s stock valued at $6,153,000 after buying an additional 11,730 shares during the last quarter. Finally, Gotham Asset Management LLC grew its holdings in Alexion Pharmaceuticals by 35.3% during the 2nd quarter. Gotham Asset Management LLC now owns 29,020 shares of the biopharmaceutical company’s stock valued at $3,531,000 after buying an additional 7,570 shares during the last quarter. Hedge funds and other institutional investors own 94.04% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) CFO Paul J. Clancy Sells 6,079 Shares” was published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/02/10/alexion-pharmaceuticals-inc-alxn-cfo-paul-j-clancy-sells-6079-shares.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.